Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

SHE:300357 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Operating Revenue	976.59	921.46	840.75	894.88	804.12	633.42
Other Revenue	3.79	3.94	7.44	1.14	3.58	2.79
Revenue	980.37	925.39	848.19	896.02	807.69	636.21
Revenue Growth (YoY)	10.01%	9.10%	-5.34%	10.94%	26.95%	-0.49%
Cost of Revenue	46.84	44.81	40.19	42.51	34.44	28.54
Gross Profit	933.53	880.58	808	853.5	773.25	607.67
Selling, General & Admin	453.36	434.65	385.28	359.63	333.97	263.18
Research & Development	119.46	119.88	112.2	106.02	87.93	61.27
Other Operating Expenses	17.74	7.84	4.57	4.53	3.78	3.27
Operating Expenses	591.09	563.23	501.05	471.43	427.23	328.01
Operating Income	342.44	317.36	306.95	382.07	346.02	279.66
Interest Expense	-0.85	-1.06	-1.31	-0.44	-0.36	-
Interest & Investment Income	33.36	35.81	32.87	28.35	29.03	24.63
Currency Exchange Gain (Loss)	0	0	0	-0	-0	-0.01
Other Non Operating Income (Expenses)	0.33	-0.34	-0.26	-0.15	-0.17	-0.17
EBT Excluding Unusual Items	375.28	351.76	338.25	409.82	374.52	304.11
Gain (Loss) on Sale of Investments	3.78	2.43	-0.67	-0.88	-0.1	2.66
Gain (Loss) on Sale of Assets	1.85	0.57	-	-0.27	-	-
Asset Writedown	-1.42	-1.42	-0.58	-43.23	-0.1	-0.01
Other Unusual Items	14.59	11.72	8.95	33.3	18.67	15.85
Pretax Income	394.09	365.06	345.96	398.75	393	322.62
Income Tax Expense	61.95	60.72	50.43	63.02	66.71	52.89
Earnings From Continuing Operations	332.15	304.34	295.52	335.73	326.29	269.72
Minority Interest in Earnings	13.45	13.48	14.66	13.05	11.7	8.72
Net Income	345.6	317.82	310.18	348.77	337.99	278.45
Net Income to Common	345.6	317.82	310.18	348.77	337.99	278.45
Net Income Growth	11.19%	2.46%	-11.06%	3.19%	21.38%	-6.65%
Shares Outstanding (Basic)	524	524	524	524	524	524
Shares Outstanding (Diluted)	524	524	524	524	524	524
Shares Change (YoY)	-0.01%	-0.00%	-	-0.00%	0.00%	-0.00%
EPS (Basic)	0.66	0.61	0.59	0.67	0.65	0.53
EPS (Diluted)	0.66	0.61	0.59	0.67	0.65	0.53
EPS Growth	11.20%	2.46%	-11.06%	3.19%	21.38%	-6.65%
Free Cash Flow	216.42	133.12	154.61	159.62	236.33	186.06
Free Cash Flow Per Share	0.41	0.25	0.29	0.30	0.45	0.35
Dividend Per Share	0.220	0.220	0.185	0.200	0.201	0.160
Dividend Growth	18.92%	18.92%	-7.50%	-0.50%	25.62%	-11.11%
Gross Margin	95.22%	95.16%	95.26%	95.25%	95.74%	95.51%
Operating Margin	34.93%	34.29%	36.19%	42.64%	42.84%	43.96%
Profit Margin	35.25%	34.34%	36.57%	38.92%	41.85%	43.77%
Free Cash Flow Margin	22.07%	14.39%	18.23%	17.82%	29.26%	29.25%
EBITDA	387.38	360.81	338.38	402.44	366.11	294.68
EBITDA Margin	39.51%	38.99%	39.89%	44.91%	45.33%	46.32%
D&A For EBITDA	44.95	43.45	31.43	20.37	20.08	15.03
EBIT	342.44	317.36	306.95	382.07	346.02	279.66
EBIT Margin	34.93%	34.29%	36.19%	42.64%	42.84%	43.96%
Effective Tax Rate	15.72%	16.63%	14.58%	15.80%	16.97%	16.39%
Revenue as Reported	980.37	925.39	848.19	896.02	807.69	636.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.